This statement in todays announcement is the part that shouts out to me
“Not only does this enable us to progress to a multiple dose study in
RP11 with high conviction but it also has important read-through implications for the
remainder of our ocular pipeline as this is the first time the RNA conjugate modality has
ever been used in a human eye.”
My thoughts are that the implications of this to all other bio tech companies working in the field of monogenic eye diseases would have to have them and the likes of Roche (who bought Spark Therapeutics) paying serious attention to PYC from both a medical discover perspective and a financial investment point of view.
I am getting excited about the future
This statement in todays announcement is the part that shouts...
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.010(8.33%) |
Mkt cap ! $513.2M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 11.0¢ | $383.6K | 3.159M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 169997 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 1549 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| PYC (ASX) Chart |